Ayurvedic Approach to Management of Mutrakruccha: A Single Case Study

Mutrakruccha, described in Ayurvedic classics as a disorder of Mutravaha Srotas, presents with painful, scanty, and burning micturition and correlates clinically with lower urinary tract infection, urethritis and cystitis. Rising antimicrobial resistance has renewed interest in integrative and herbal approaches for early-stage urinary symptoms. This case study evaluates the efficacy of an oral Ayurvedic Shamana Chikitsa protocol in a 32-year-old female presenting with burning micturition, increased frequency of 8–10 times per day, urgency, and lower abdominal pain for seven days. Clinical examination revealed mild suprapubic tenderness with Pitta-Vata dominant Nadi Detailed clinical examination and laboratory investigations revealed the presence of pus cells and mild bacterial infection in urine examination. Based on Ayurvedic assessment, the condition was diagnosed as Pittaja Mutrakruccha. The patient was managed for 14 days with Gokshura Churna 5g twice daily before food, Chandraprabha Vati 500mg twice daily after food, and Yavakshar 250mg twice daily with Gokshura Kashaya 15ml. Pathya-Apathya including barley water, coconut water, and buttermilk was advised, with avoidance of spicy, salty, fermented foods and suppression of natural urges. Assessment was based on subjective symptoms and urine routine on day 0 and day 14. By day seven, burning micturition and frequency reduced by 70 percent with improved sleep and comfort. By day fourteen, symptoms resolved completely and repeat urine routine showed pus cells 1–2 per high power field with no albumin. No adverse drug reactions were observed and patient compliance was good. The protocol aligns with Charaka Samhita Chikitsa Sthana 26, which recommends Mutrala and Pittahara drugs for Mutrakruccha. This case suggests that targeted Shamana Chikitsa using Mutrala, Pittashamaka, and Mutra Shodhaka drugs can effectively and safely manage uncomplicated Mutrakruccha, supporting the role of Ayurveda in early-stage lower urinary tract symptoms and warranting further controlled studies.